白蛋白结合型紫杉醇联合奈达铂治疗食管癌的效果及对3年生存率、毒副反应的影响  

Effects of Abraxane and Paclitaxel Respectively Combined with Nedaplatin in the Treatment of Esophageal Cancer and 3-year Survival Rate and Toxic and Side Effects

作　　者：赵红丹[1] 郭康[1] 白力允[1] 宋士军[1] ZHAO Hongdan;GUO Kang;BAI Liyun;SONG Shijun(The Second Department of Oncology,the Third Affiliated Hospital of Xinxiang Medical College,Xinxiang,Henan 453000,China)

机构地区：[1]新乡医学院第三附属医院肿瘤内二科,河南新乡453000

出　　处：《湖北民族大学学报（医学版）》2022年第2期53-56,65,共5页Journal of Hubei Minzu University(Medical Edition)

摘　　要：目的探究白蛋白结合型紫杉醇联合奈达铂治疗食管癌的效果及对3年生存率、毒副反应的影响。方法选取医院2019年1月-2021年3月收治的42例食管癌患者为研究对象,采用随机数字表法将患者分为对照组和观察组各21例,对照组采用紫杉醇联合奈达铂治疗,观察组采用白蛋白结合型紫杉醇联合奈达铂治疗,比较两组患者临床疗效、毒副反应发生情况以及生存率。结果观察组疾病客观缓解率(ORR)显著高于对照组(P<0.05);两组治疗后血清肿瘤标志物:癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(Cyfra21-1)水平均有下降(P<0.05),观察组明显低于对照组(P<0.05);观察组恶心呕吐、腹泻发生率低于对照组(P<0.05);两组随访总生存率(OS)比较差异无统计学意义(χ^(2)=0.005,P=0.942)。结论白蛋白结合型紫杉醇联合奈达铂治疗食管癌患者可显著提升临床疗效、降低患者血清肿瘤标志物水平、提升3年存活率与减轻毒副反应,安全性高,值得临床推广。Objective To explore the effects of Abraxane and paclitaxel respectively combined with nedaplatin in the treatment of esophageal cancer,and 3-year survival rate and toxic and side effects.Methods A total of 42 esophageal cancer patients admitted to the hospital from January 2019 to March 2021 were selected as the research subjects.They were divided into control group and experimental group by random number table method,21 cases in each group.Patients in control group were treated with paclitaxel combined with nedaplatin,while those in experimental group were treated with Abraxane combined with nedaplatin.Clinical effects,the incidence of toxic and side effects,and survival rate were compared between the two groups.Results The ORR of experimental group was 71.43%(15/21),which was significantly higher than that of control group[38.09%(8/21)](P<0.05).There was no statistically significant difference in serum tumor markers between the two groups before treatment(P>0.05).After treatment,the levels of carcinoembryonic antigen(CEA)and cytokeratin fragment antigen 21-1(Cyfra21-1)decreased(P<0.05),and were lower in experimental group than in control group(P<0.05).Toxic and side effects,including bone marrow suppression,nausea and vomiting,diarrhea and low platelet count were observed in the two groups during treatment.There was no statistically significant difference in the incidence rates of bone marrow suppression and low platelet count between the two groups(P>0.05).The incidence rates of grade III-IV nausea and vomiting and grade III-IV diarrhea in experimental group(4.76%and 4.76%)were lower than those in control group(52.38%and 33.34%)(P<0.05).The control group was followed up for 10~36 months,and 10 patients died during follow-up.The median survival time was 26 months,and the overall survival(OS)rate was 20.10%.The observation group was followed up for 3~36 months,and 9 patients died during follow-up.The median survival time was 23 months,and the OS rate was 32.70%.There was no statistically significant difference

关 键 词：食管癌 白蛋白结合型紫杉醇 紫杉醇 奈达铂 

分 类 号：R735.1[医药卫生—肿瘤]